Material Event Form 8 K

Item 8.01 Other Events.

On July 22, 2024, aTyr Pharma, Inc. (the "Company") announced that it has completed enrollment in its global pivotal Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis (the "EFZO-FIT study"). The EFZO-FIT study enrolled 268 patients at 85 centers in 9 countries, exceeding target enrollment. Topline data from the EFZO-FIT study are expected in the third quarter of 2025.

Forward-Looking Statements

Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements regarding the anticipated timing and results of data from the Company's Phase 3 EFZO-FIT study. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of these results will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties associated with research and development of pharmaceutical product candidates, as well as risks and uncertainties inherent in the Company's business, including those described in the Company's other filings with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.